1-7 of 7
Aradhana Awasthi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Polatuzumab Vedotin; Antibody Drug Conjugates (ADC, anti-CD79b-vc-MMAE, PV) Significantly Enhances in-Vitro Cell Death Against CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL) and Improved Overall Survival Against Rituximab Sensitive/Resistant-BL NSG Xenograft Mice

Aradhana Awasthi, Janet Ayello, MS, Carmella van de Ven, MA, Asana Love, Mitchell S. Cairo, MD
Journal: Blood
Blood (2016) 128 (22): 4126.
https://doi.org/10.1182/blood.V128.22.4126.4126
Published: 2016
Journal Articles

A Comparative Global Phosphoproteomics Analysis of Obinutuzumab (GA101) Versus Rituximab (RTX) Against RTX Sensitive and Resistant Burkitt Lymphoma (BL) Demonstrates Differential Phosphorylation of Signaling Pathways Proteins

Aradhana Awasthi, PhD, Delphine C.M. Rolland, PharmD, PhD, Mona Elmacken, MD, Christopher Reggio, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Venkatesha Basrur, PhD, Kevin Conlon, MS, Damian Fermin, PhD, Matthew J. Barth, MD, Kojo S.J. Elenitoba-Johnson, MD, Megan S Lim, MD PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2014) 124 (21): 5481.
https://doi.org/10.1182/blood.V124.21.5481.5481
Published: 2014
Journal Articles

Comparative Study of Obinutuzumab (GA101) Vs. Rituximab Against CD20 + rituximab-Sensitive and -Resistant Burkitt (BL) and Acute Lymphoblastic Leukemia (B-ALL): Potential Targeted Therapy in Patients with High Risk BL and Pre-B-ALL

Aradhana Awasthi, PhD, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Mona Elmacken, MD, Christopher Reggio, Matthew J. Barth, MD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2014) 124 (21): 2251.
https://doi.org/10.1182/blood.V124.21.2251.2251
Published: 2014
Journal Articles

Obinutuzumab (GA101) Significantly Improves Survival In CD20 Positive Pre-B Cell Lymphoblastic Leukemia (pre-B-ALL) Xenograft Models Compared To Rituximab (RTX): Potential Targeted Therapy In Patients With High Risk Pre-B-ALL

Aradhana Awasthi, Ph.D, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Stefan Hovy, Mitchell S. Cairo, MD
Journal: Blood
Blood (2013) 122 (21): 3068.
https://doi.org/10.1182/blood.V122.21.3068.3068
Published: 2013
Journal Articles

The Acquirement Of Rituximab Resistance Is Associated With De-Regulation Of The PI3K/Akt/mTOR Signaling Pathway Leading To Chemotherapy Resistance In Burkitt Lymphoma Pre-Clinical Models

Sarah Frys, BSc, Andrew Skomra, Natalie M Czuczman, BSc, Cory Mavis, BSc, MSc, Delphine C.M. Rolland, PharmD, PhD, Megan Lim, MD, PhD, Aradhana Awasthi, Ph.D, Mitchell S. Cairo, MD, Myron S. Czuczman, MD, Francisco J. Hernandez-Ilizaliturri, MD, Matthew J. Barth, MD
Journal: Blood
Blood (2013) 122 (21): 5144.
https://doi.org/10.1182/blood.V122.21.5144.5144
Published: 2013
Journal Articles

Global Phosphoproteomics Analysis Of Burkitt Lymphoma (BL) Demonstrates Abnormal Protein Phosphorylation In BCR, Spliceosome, mTOR and Chemokine Signaling Pathways In Rituximab Induced Resistant BL

Aradhana Awasthi, Ph.D, Delphine Rolland, Ph.D, Matthew J. Barth, MD, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Myron S. Czuczman, MD, Kojo S.J. Elenitoba-Johnson, MD, Megan Lim, MD, PhD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2013) 122 (21): 928.
https://doi.org/10.1182/blood.V122.21.928.928
Published: 2013
Journal Articles

Obinutuzumab (GA101) Significantly Enhances Cell Death and ADCC Compared to Rituximab Against CD20 + sensitive and Rituximab Resistant B-Cell Non-Hodgkin Lymphoma (NHL) and Lymphoblastic Leukemia (BLL)

Aradhana Awasthi Tiwari, PhD, Janet Ayello, MS, MT(ASCP), Carmella van de Ven, MA, Danielle Glassman, Anthony Sabulski, Matthew J. Barth, MD, Mitchell S. Cairo, MD
Journal: Blood
Blood (2012) 120 (21): 4865.
https://doi.org/10.1182/blood.V120.21.4865.4865
Published: 2012